These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 24004674)

  • 1. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.
    Etemadmoghadam D; Au-Yeung G; Wall M; Mitchell C; Kansara M; Loehrer E; Batzios C; George J; Ftouni S; Weir BA; Carter S; Gresshoff I; Mileshkin L; Rischin D; Hahn WC; Waring PM; Getz G; Cullinane C; Campbell LJ; Bowtell DD
    Clin Cancer Res; 2013 Nov; 19(21):5960-71. PubMed ID: 24004674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
    Au-Yeung G; Lang F; Azar WJ; Mitchell C; Jarman KE; Lackovic K; Aziz D; Cullinane C; Pearson RB; Mileshkin L; Rischin D; Karst AM; Drapkin R; Etemadmoghadam D; Bowtell DD
    Clin Cancer Res; 2017 Apr; 23(7):1862-1874. PubMed ID: 27663592
    [No Abstract]   [Full Text] [Related]  

  • 3. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
    Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
    Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
    Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K
    Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression.
    Yang L; Fang D; Chen H; Lu Y; Dong Z; Ding HF; Jing Q; Su SB; Huang S
    Oncotarget; 2015 Aug; 6(25):20801-12. PubMed ID: 26204491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional characterization of the 19q12 amplicon in grade III breast cancers.
    Natrajan R; Mackay A; Wilkerson PM; Lambros MB; Wetterskog D; Arnedos M; Shiu KK; Geyer FC; Langerød A; Kreike B; Reyal F; Horlings HM; van de Vijver MJ; Palacios J; Weigelt B; Reis-Filho JS
    Breast Cancer Res; 2012 Mar; 14(2):R53. PubMed ID: 22433433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.
    Caldon CE; Sergio CM; Kang J; Muthukaruppan A; Boersma MN; Stone A; Barraclough J; Lee CS; Black MA; Miller LD; Gee JM; Nicholson RI; Sutherland RL; Print CG; Musgrove EA
    Mol Cancer Ther; 2012 Jul; 11(7):1488-99. PubMed ID: 22564725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
    J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.
    Scaltriti M; Eichhorn PJ; Cortés J; Prudkin L; Aura C; Jiménez J; Chandarlapaty S; Serra V; Prat A; Ibrahim YH; Guzmán M; Gili M; Rodríguez O; Rodríguez S; Pérez J; Green SR; Mai S; Rosen N; Hudis C; Baselga J
    Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3761-6. PubMed ID: 21321214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic lethality between CCNE1 amplification and loss of BRCA1.
    Etemadmoghadam D; Weir BA; Au-Yeung G; Alsop K; Mitchell G; George J; ; Davis S; D'Andrea AD; Simpson K; Hahn WC; Bowtell DD
    Proc Natl Acad Sci U S A; 2013 Nov; 110(48):19489-94. PubMed ID: 24218601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin E as a potential therapeutic target in high grade serous ovarian cancer.
    Kanska J; Zakhour M; Taylor-Harding B; Karlan BY; Wiedemeyer WR
    Gynecol Oncol; 2016 Oct; 143(1):152-158. PubMed ID: 27461360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer.
    Aziz D; Lee C; Chin V; Fernandez KJ; Phan Z; ; ; Waring P; Caldon CE
    J Pathol Clin Res; 2022 Jul; 8(4):355-370. PubMed ID: 35384378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma.
    Sonntag R; Giebeler N; Nevzorova YA; Bangen JM; Fahrenkamp D; Lambertz D; Haas U; Hu W; Gassler N; Cubero FJ; Müller-Newen G; Abdallah AT; Weiskirchen R; Ticconi F; Costa IG; Barbacid M; Trautwein C; Liedtke C
    Proc Natl Acad Sci U S A; 2018 Sep; 115(37):9282-9287. PubMed ID: 30150405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Therapeutic Resistance and Multinucleate Giant Cells in CCNE1-Amplified HR-Proficient Ovarian Cancer.
    Bai S; Taylor SE; Jamalruddin MA; McGonigal S; Grimley E; Yang D; Bernstein KA; Buckanovich RJ
    Mol Cancer Ther; 2022 Sep; 21(9):1473-1484. PubMed ID: 35732503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCNE1 amplification is associated with liver metastasis in gastric carcinoma.
    Kim B; Shin HC; Heo YJ; Ha SY; Jang KT; Kim ST; Kang WK; Lee J; Kim KM
    Pathol Res Pract; 2019 Aug; 215(8):152434. PubMed ID: 31178228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas.
    Etemadmoghadam D; deFazio A; Beroukhim R; Mermel C; George J; Getz G; Tothill R; Okamoto A; Raeder MB; Harnett P; Lade S; Akslen LA; Tinker AV; Locandro B; Alsop K; Chiew YE; Traficante N; Fereday S; Johnson D; Fox S; Sellers W; Urashima M; Salvesen HB; Meyerson M; Bowtell D;
    Clin Cancer Res; 2009 Feb; 15(4):1417-27. PubMed ID: 19193619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer.
    Etemadmoghadam D; George J; Cowin PA; Cullinane C; Kansara M; ; Gorringe KL; Smyth GK; Bowtell DD
    PLoS One; 2010 Nov; 5(11):e15498. PubMed ID: 21103391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
    Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
    Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.
    Cocco E; Lopez S; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; Menderes G; Zammataro L; Buza N; Hui P; Wong S; Zhao S; Bai Y; Rimm DL; Ratner E; Litkouhi B; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Br J Cancer; 2016 Jul; 115(3):303-11. PubMed ID: 27351214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer.
    Noske A; Brandt S; Valtcheva N; Wagner U; Zhong Q; Bellini E; Fink D; Obermann EC; Moch H; Wild PJ
    Oncotarget; 2017 Feb; 8(9):14794-14805. PubMed ID: 27582547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.